Results Summary Sample Clauses

Results Summary. A discussion of the results of the analysis.

Results Summary. Due to the coronavirus pandemic and ordered school-building closure, state assessments were not given in the spring of 2020 with the exception of ACT as it was administered prior to the closure of schools. Forward Proficiency ACT Aspire Proficiency ACT Proficiency Pretest Results: Early Read

Results Summary. Ninety-seven percent of the students who started their DPI cohort year earned at least 5-6 credits their final year.

Results Summary. Eighty-four percent of students who start their high school cohort at another school earned at least 5-6 credits. (Three students out of nineteen did not meet this requirement.)

Results Summary. Tabel 5 Summary overview.

Results Summary. After looking at the various iterations of regression models, the best model to use is the first-differences model. The first-differences model allows us to isolate the impact arising from the Basel III Agreement since we control for factors that make each bank unique such as their culture, which can influence their lending decisions. The model also allows us to correct for issues with auto-correlation and stationarity that arise in the OLS Model. With the first- differences model, for the most part a negative relationship exists between bank capital ratios and C&I loans across all bank categories. Thus the hypothesized negative relationship between bank capital and commercial and industrial loans holds true. While the negative relationship does hold for regional and community-based banks, the impact on C&I loans is minimal. We are only talking about a decline of .01% to .02% in a bank’s C&I loan book, which runs in the hundreds of millions to several billion dollars. While not statistically significant, the universal banks experience the largest impact on C&I loans from a one percent increase in the tier one-risk based capital ratio. An important point to highlight and keep in mind is that when looking at these models, we are always talking in terms of a one- percentage point increase in the capital ratios. For banks that is a large increase in capital over just a quarter and such an increase would be more likely to occur over several quarters.

Results Summary. 16 CyDex Inc. ▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ - (▇▇▇) ▇▇▇-▇▇▇▇ - FAX (▇▇▇) ▇▇▇-▇▇▇▇ - E-mail: ▇▇_▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇ (CYDEX, INC. LOGO) BACKGROUND INFORMATION FOR USING THE CAPTISOL(R) DOSING MATRIX The enclosed tables contain summary dosing information for Captisol(R) by different routes for various species. There is one summary page for each route, which contains information for mice, rats, rabbits, dogs, and non-human primates. Routes of administration discussed include intravenous, subcutaneous, intramuscular, intraperitoneal and oral. For intravenous studies, an extensive database is available for the rat and dog, with less information being available for the mouse, rabbit and monkey. For other routes of administration data are limited to rats, rabbits and monkeys for subcutaneous administration, rats for intramuscular administration, and rats and dogs for oral administration. Because data is limited for some routes and species, extrapolations were sometimes used in determining the allowable dose. In other instances where data is limited, CyDex requires consultation prior to dosing. In each case the allowable dose is the Captisol(R) dose that can be administered without prior consultation and/or specific approval of CyDex. The doses listed are based on data from studies conducted with Captisol(R) or are an extrapolation from those studies. At the doses listed in the matrix adaptive responses may be present, but toxic effects would not be anticipated. In addition to considering the allowable Captisol(R) dose, one must be cognizant of the two variables (concentration and dose volume) determining the dose. In using the matrix table, these two variables may be adjusted to best fit the needs of the client. However, the allowable Captisol(R) dose and allowable Captisol(R) concentration may not be exceed without prior approval from CyDex. The concentration listed on the matrix is based on the concentration used in the majority of the toxicity studies conducted with Captisol(R). As implied above, lesser concentrations may be administered as long as the total dose does not exceed the approved limit set forth in the Dosing Matrix. With respect to dose volumes, those listed in the Captisol(R) dosing matrix represent volumes that are recognized as appropriate for the species and route (based on published literature). CyDex recognizes that individual laboratories may have established different dosing volumes for use in a particular species for a given route. I...

Results Summary. Grade K 1 2 3 Overall

Results Summary. Due to the coronavirus pandemic and school-building closure, this assessment was not given in the spring of 2020.